WCM
TGTX icon

Weld Capital Management’s TG Therapeutics TGTX Stock Holding History

Weld Capital Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-24,725
Closed -$139K – 924
2019
Q3 		$139K Buy
+24,725
New +$172K 0.03% 722

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Weld Capital Management's TGTX Position: Q4 2019 in Review

Weld Capital Management sold out of TG Therapeutics (TGTX) in Q4 2019, closing a stake of 24,725 shares — an estimated $139K sold.

Weld Capital Management first reported a position in TGTX in Q3 2019 and held it in 1 quarter. The position peaked at $139K in Q3 2019. 135 funds tracked by Wall St. Rank hold TGTX as of Q4 2019.

  • Weld Capital Management reported no remaining TG Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Weld Capital Management sold 24,725 TG Therapeutics shares in Q4 2019, an estimated $139K.
  • Weld Capital Management first reported a position in TG Therapeutics in Q3 2019 and held it in 1 quarter.
  • Weld Capital Management's TG Therapeutics position peaked at $139K in Q3 2019.
  • 135 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2019.

Based on Weld Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.